Investors Purchase High Volume of Astera Labs Call Options (NASDAQ:ALAB)

Astera Labs, Inc. (NASDAQ:ALAB) was the recipient of unusually large options trading activity on Friday. Traders acquired 39,399 call options on the stock. This represents an increase of approximately 54% compared to the typical volume of 25,506 call options.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ALAB. Barclays set a $165.00 price objective on shares of Astera Labs in a research report on Thursday, January 15th. Weiss Ratings cut shares of Astera Labs from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, February 23rd. Loop Capital assumed coverage on shares of Astera Labs in a research note on Thursday, March 5th. They issued a “buy” rating and a $250.00 target price for the company. Citigroup assumed coverage on shares of Astera Labs in a research note on Thursday, April 2nd. They issued a “buy” rating and a $200.00 target price for the company. Finally, Royal Bank Of Canada assumed coverage on shares of Astera Labs in a research note on Wednesday, January 14th. They issued an “outperform” rating and a $225.00 target price for the company. Fifteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Astera Labs presently has an average rating of “Moderate Buy” and a consensus target price of $199.44.

Insider Transactions at Astera Labs

In other Astera Labs news, CFO Michael Truett Tate sold 12,001 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $123.81, for a total transaction of $1,485,843.81. Following the completion of the sale, the chief financial officer owned 192,083 shares in the company, valued at approximately $23,781,796.23. The trade was a 5.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, General Counsel Philip Mazzara sold 10,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $107.77, for a total transaction of $1,077,700.00. Following the sale, the general counsel owned 118,084 shares of the company’s stock, valued at $12,725,912.68. The trade was a 7.81% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 577,292 shares of company stock worth $69,495,249 over the last ninety days. 12.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Astera Labs

Several hedge funds have recently bought and sold shares of the company. Nordea Investment Management AB bought a new position in shares of Astera Labs during the fourth quarter worth approximately $2,028,000. Geneva Partners LLC bought a new position in shares of Astera Labs during the third quarter worth approximately $1,876,000. Numerai GP LLC increased its holdings in shares of Astera Labs by 153.1% during the third quarter. Numerai GP LLC now owns 13,212 shares of the company’s stock worth $2,587,000 after purchasing an additional 7,992 shares during the period. Handelsbanken Fonder AB increased its holdings in shares of Astera Labs by 289.5% during the third quarter. Handelsbanken Fonder AB now owns 126,200 shares of the company’s stock worth $24,710,000 after purchasing an additional 93,800 shares during the period. Finally, Corient Private Wealth LLC bought a new position in shares of Astera Labs during the second quarter worth approximately $543,000. 60.47% of the stock is currently owned by institutional investors and hedge funds.

Astera Labs Trading Up 13.7%

Shares of Astera Labs stock traded up $17.78 during trading hours on Friday, reaching $147.24. 6,894,482 shares of the company’s stock were exchanged, compared to its average volume of 5,108,590. The company has a 50 day moving average of $128.14 and a two-hundred day moving average of $156.21. Astera Labs has a fifty-two week low of $52.56 and a fifty-two week high of $262.90. The stock has a market cap of $25.21 billion, a P/E ratio of 120.79, a P/E/G ratio of 2.47 and a beta of 1.78.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings data on Tuesday, February 10th. The company reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.07. Astera Labs had a net margin of 25.70% and a return on equity of 16.12%. The company had revenue of $270.58 million during the quarter, compared to the consensus estimate of $249.46 million. During the same period in the prior year, the business posted $0.37 EPS. The company’s quarterly revenue was up 91.8% on a year-over-year basis. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. As a group, analysts expect that Astera Labs will post 0.34 earnings per share for the current fiscal year.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.